Back to Search
Start Over
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
- Source :
- Annals of the rheumatic diseases, 79(7), 851-858. BMJ Publishing Group, Annals of the Rheumatic Diseases, Annals of the Rheumatic Diseases, BMJ Publishing Group, 2020, 79 (7), pp.851-858. ⟨10.1136/annrheumdis-2020-217877⟩, Annals of the Rheumatic Diseases, 2020, 79 (7), pp.851-858. ⟨10.1136/annrheumdis-2020-217877⟩
- Publication Year :
- 2020
-
Abstract
- International audience; The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a ‘living document’ and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.
- Subjects :
- antirheumatic agents
MESH: Coronavirus Infections
Quality indicators
Disease
MESH: Rheumatic Diseases
0302 clinical medicine
Epidemiology
MESH: Musculoskeletal Diseases
Medicine
Immunology and Allergy
MESH: COVID-19
030212 general & internal medicine
skin and connective tissue diseases
Potential impact
[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Health services research
epidemiology
health services research
patient care team
quality indicators, health care
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
MESH: Betacoronavirus
MESH: Immunosuppressive Agents
medicine.medical_specialty
MESH: Pandemics
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Immunology
MESH: Societies, Medical
Context (language use)
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Rheumatology
MESH: Rheumatology
MESH: SARS-CoV-2
MESH: Clinical Laboratory Techniques
030203 arthritis & rheumatology
MESH: Humans
business.industry
Health care
MESH: COVID-19 Testing
Living document
MESH: Pneumonia, Viral
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Family medicine
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
MESH: Europe
business
MESH: Glucocorticoids
Subjects
Details
- Language :
- English
- ISSN :
- 00034967 and 14682060
- Database :
- OpenAIRE
- Journal :
- Annals of the rheumatic diseases, 79(7), 851-858. BMJ Publishing Group, Annals of the Rheumatic Diseases, Annals of the Rheumatic Diseases, BMJ Publishing Group, 2020, 79 (7), pp.851-858. ⟨10.1136/annrheumdis-2020-217877⟩, Annals of the Rheumatic Diseases, 2020, 79 (7), pp.851-858. ⟨10.1136/annrheumdis-2020-217877⟩
- Accession number :
- edsair.doi.dedup.....a2931004805c7f6586513349281f7876